A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02706405

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:01.359405+00:00

Published At

2022-08-24T00:00:00+00:00

Record Updated At

2022-08-24

Results Posted At

2022-08-24

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-08-24"

protocolSection.identificationModule.nctId

"NCT02706405"

protocolSection.identificationModule.officialTitle

"A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2022-08-24"

Study condition terms

• Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.